Prolonged-release ciprofloxacin

American Journal of Drug Delivery

Volumn 4, Issue 2, 2006, Pages 113-120

  Foster, Rachel H ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTICOAGULANT AGENT; CALCIUM; CIPROFLOXACIN; CYCLOSPORIN; GLIBENCLAMIDE; METHOTREXATE; OMEPRAZOLE; PHENYTOIN; POLYMER; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; THEOPHYLLINE;

AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CYSTITIS; DIARRHEA; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG RELEASE; DRUG TOLERABILITY; DRUG URINE LEVEL; EROSION; HEADACHE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAXIMUM ALLOWABLE CONCENTRATION; MYCOSIS; NAUSEA; PRIORITY JOURNAL; PROTEUS MIRABILIS; REVIEW; STOMACH; STOMACH ACID; SUSTAINED DRUG RELEASE; TABLET; UPPER GASTROINTESTINAL TRACT; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; VAGINITIS;

EID: 33745911911     PISSN: 11759038     EISSN: 11759038     Source Type: Journal    
DOI: 10.2165/00137696-200604020-00007     Document Type: Review

References (33)

1. Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003; 20 (6): 461-97
2. Wu J. Gastric retentive dosage forms. Drug Delivery Supplement. Cambridge: PJB Publications, 2005: 18-9
3. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 1996; 136 (1-2): 117-39
4. Hoffman A, Stepensky D, Lavy E, et al. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004; 277 (1-2): 141-53
5. Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Release 2003 Jun 24; 90 (2): 143-62
6. Depomed, Inc. Technology: overview [online]. Available from URL: http://www.depomedinc.com/technology_overview.htm [Accessed 2005 Dec 5]
7. Gusler G, Gorsline J, Levy G, et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001 Jun; 41 (6): 655-61
8. Harder S, Fuhr U, Beermann D, et al. Ciprofloxacin absorption in different regions of the human gastrointestinal tract: investigations with the hf-capsule. Br J Clin Pharmacol 1990 Jul; 30 (1): 35-9
9. Washington CB, Hou SYE, Campanella C, et al. Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers. J Clin Pharmacol 2005 Nov; 45 (11): 1236-44
10. Louie-Helm J, Fell R, Shell JN, et al. Pharmacokinetics of ciprofloxacin gastric retentive (GR™) tablets in healthy volunteers [abstract]. 28th Annual Symposium of the Controlled Release Society; 2001 Jun 23-27; San Diego (CA)
11. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability and safety of a novel once-daily extended-release metformin in patients with type II diabetes mellitus. Diabetes Care 2006 Apr; 29 (4): 759-64
12. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002 Jul 8; 113 Suppl. 1A: 5S-13S
13. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America. Clin Infect Dis 1999 Oct; 29 (4): 745-58
14. Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med 2002 Jul; 113 Suppl. 1A: 45S-54S
15. Stahlmann K, Lode H. Toxicity of quinolones. Drugs 1999; 58 Suppl. 2: 37-42
16. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51 (6): 1019-74
17. Fourcroy JL, Berner B, Chiang YK, et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005 Oct; 49 (10): 4137-43
18. Blondeau JM. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. Drugs 2004; 64 (6): 611-28
19. Waugh J, Keating GM. Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis. Drugs Aging 2004; 21 (1): 55-64
20. Shell JW, Louie-Helm J. United States Patent 5,972,389; 1999 Oct 26 [online]. Available from URL: http://www.uspto.gov/patft/index.html [Accessed 2006 Mar 27]
21. Depomed, Inc. In vitro dissolution data for ProQuin® and Cipro® XR. Menlo Park (CA): Depomed, Inc., 2005 [Data on file] 22. Depomed, Inc. Technology: erosional [online]. Available from URL: http://www.depomedinc.com/ technology_erosional.htm [Accessed 2005 Dec 5]
22. Hooper DC. Mode of action of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 6-10
23. Depomed, Inc. ProQuin® XR (ciprofloxacin hydrochloride) extended-release tablets, 500mg: package insert. Menlo Park (CA): Depomed, Inc., 2005
24. Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990 Dec; 19 (6): 434-61
25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. Report no: M100-S16. Vol 26 No. 3. Wayne (PA): Clinical and Laboratory Standards Institute, 2006 Jan
26. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29-36
27. Meagher AK, Forrest A, Dalhoff A, et al. Novel pharmacokinetic- pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2061-8
28. Washington C, Hou E, Hughes N, et al. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. Am J Health-Sys Phar 2006; 63 (7): 653-6
29. Bayer HealthCare. Cipro® XR (ciprofloxacin extended-release tablets). Prescribing information. West Haven (CT): Bayer Pharmaceuticals Corporation, 2005
30. US Food and Drug Administration. Center for Drug Evaluation and Research. Cipro XR (ciprofloxacin) extended-release tablets. Bayer Corporation application number 21-473. Clinical pharmacology biopharmaceutics review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-473_Cipro. htm [Accessed 2006 Apr 20]
31. Depomed, Inc. Integrated clinical statistical study report. Randomized, double-blind, parallel-group study to compare the safety and efficacy of ciprofloxacin gastric retentive (GR.) QD and ciprofloxacin immediate-release (IR) BID in the treatment of uncomplicated female urinary tract infection. Menlo Park (CA): Depomed, Inc., 2004 Jun 30 [Data on file]
32. Berner B, Cramer JM, Chiang Y-K, et al. Randomized, double-blind comparison of the safety and efficacy of a novel once daily and conventional twice daily formulation of ciprofloxacin in uncomplicated urinary tract infection [abstract no. 95]. J Urol 2004; 171 (4 Suppl.): 25
33. Depomed, Inc. Depomed and Madaus S.r.l. announce acceptance of the application for approval of ProQuin. XR in Sweden [media release; online]. Available from URL: http://www.depomedinc.com [Accessed 2006 Apr 3]